The New Evidence Engine: How Biopharma is Merging RWE and Market Access

CHICAGO, IL – October 08, 2026 – The days of launching a breakthrough therapy based solely on a pristine, highly controlled Phase III clinical trial are effectively over. Today, global health technology assessment (HTA) bodies and payers demand to know how a treatment performs in the messy, unstructured reality of everyday clinical practice. To navigate this evolving landscape, the life sciences industry is fundamentally rewiring how it captures and leverages data. Today's announcement of a strategic partnership between EVERSANA, a global commercial services provider, and Pulse Infoframe, a real-world evidence (RWE) specialist, highlights this critical structural shift.

The collaboration aims to merge EVERSANA's end-to-end commercialization, market access, and health economics and outcomes research (HEOR) expertise with the proprietary RWE generation capabilities of Pulse Infoframe. The goal is ambitious but necessary: creating a single, continuous evidence engine for pharmaceutical and medical device manufacturers. By capturing data directly from sites and patients and carrying it seamlessly through to HTA-grade reporting, the alliance reflects a broader strategic imperative to prove lasting value in a rapidly changing healthcare economy.

Unifying the Pipeline: The Demand for Continuous Data

Regulatory bodies like the FDA and the EMA, alongside the newly implemented European HTA Regulation (EUHTAR), have fundamentally raised the bar for market access. It is no longer sufficient to hand over a static dossier of clinical trial results at the end of a development cycle. Payers require continuous, regulatory-grade real-world data from early clinical development straight through to post-launch commercialization.

Historically, biopharma companies treated clinical evidence generation and commercial market access as distinct, siloed operations. A contract research organization might handle the initial trial, while a separate commercialization vendor would later scramble to build a health economics model based on fragmented, retrospective real-world data.

This disjointed approach is exactly what the new alliance seeks to eliminate. By integrating their operations, the two entities are building a robust bridge between clinical data capture and commercial strategy. Pulse Infoframe's cloud-based platform, healthie™, is designed to ingest diverse data sets—from electronic health records and claims data to patient-reported outcomes—and structure them to global standards like OMOP and CDISC.

This structured, regulatory-grade data is then fed directly into EVERSANA's HEOR and commercialization workflows, which are powered by their proprietary ACTICS platform and Orchestrate Operating System. The result is an unbroken chain of evidence. Health economists and market access strategists no longer have to wait for retrospective data dumps; they can build global value dossiers and reimbursement strategies using a continuous flow of real-time, real-world patient insights.

Cracking the Rare Disease Data Deficit

The need for a continuous evidence engine is most acute in complex therapeutic areas with substantial unmet needs, particularly rare diseases and oncology. In these specialized fields, traditional randomized controlled trials are often ethically fraught, logistically impossible, or severely delayed by patient recruitment bottlenecks.

To overcome this severe data deficit, the industry is increasingly relying on external control arms (ECAs) and natural history registries. This is where the specialized capabilities of the new partnership become a critical strategic asset. Pulse Infoframe has a documented track record of launching decentralized, participant-driven registries and generating regulatory-ready external comparator arms.

Industry insiders note that in complex conditions like rare genetic kidney diseases or Dilated Cardiomyopathy, the ability to aggregate longitudinal data across multi-site registries using a uniform disease model is transformative. It allows drug developers to contextualize single-arm trial results, proving to regulators that a new therapy significantly alters the natural progression of a disease.

"Real-world evidence has never been more critical as pharmaceutical companies work to develop the best strategies to bring innovative therapies to patients," noted Mark Thierer, Chief Executive Officer of EVERSANA. "By pairing our deep commercial and health economics expertise with Pulse Infoframe's robust registry expertise in complex conditions, including rare disease and oncology, we can bring unmatched solutions to customers to help improve market access."

When registry data is rigorously mapped to regulatory standards, it ceases to be mere observational trivia and becomes actionable proof of efficacy. For a biotech founder trying to navigate the notorious gap between orphan drug designation and commercial viability, this integrated approach to ECAs can be the difference between a successful global launch and a costly regulatory stalemate.

The Vendor Consolidation Wave

Viewed through a broader business-to-business lens, this strategic partnership is a clear indicator of the ongoing vendor consolidation wave sweeping the life sciences commercialization sector. Mid-sized and specialized service providers are increasingly forming strategic alliances to rival the scale and integrated offerings of legacy giant contract research organizations like IQVIA, Parexel, and Syneos Health.

These legacy giants have spent years acquiring data analytics firms and building massive, proprietary databases of claims and electronic health records. To compete effectively, independent providers must offer something equally comprehensive but perhaps more agile and specialized.

By joining forces, EVERSANA and Pulse Infoframe are executing precisely that strategy. They are creating a unified offering that spans the full arc of evidence generation: global site-network and feasibility assessments, study design, direct data capture, and sophisticated HTA-grade reporting. This allows them to offer pharmaceutical and medical device manufacturers a seamless solution without the administrative burden of managing multiple, disparate vendor contracts.

Furthermore, this partnership directly challenges specialized RWD providers in specific therapeutic verticals. While some competitors excel at curating de-identified EHR data from oncology practices, this new alliance counters with a broader therapeutic mandate and a direct, built-in pipeline to global market access and reimbursement strategy. It is a strategic play that recognizes RWE is no longer just a retrospective research tool—it is the foundational currency of modern drug commercialization.

Engineering a Seamless Arc of Evidence

Ultimately, the success of a modern therapeutic launch hinges on the quality and continuity of its underlying data. Regulators demand proof of safety and efficacy; payers demand proof of economic value; and patients demand proof that a treatment will actually improve their daily lives. Meeting all three demands simultaneously requires a level of operational synchronization that the industry has historically struggled to achieve.

The technological architecture underpinning this new partnership is designed specifically to address this synchronization. By utilizing advanced natural language processing to extract clinical information from free-text notes and facilitating patient-centric data collection from caregivers and clinicians, the combined platform ensures that no valuable insight is lost in translation.

"Our platform was built to generate regulatory-grade evidence directly from sites and patients," stated Femida Gwadry-Sridhar, Chief Executive Officer of Pulse Infoframe. "Working with EVERSANA connects that evidence to the regulatory, reimbursement, and commercial decisions it needs to support, at global scale."

The two organizations will formally showcase their collaborative capabilities at ISPOR Europe 2026, scheduled for November 8-11 in Vienna, Austria. There, health economists and market access directors will be able to evaluate the mechanics of this continuous evidence engine firsthand.

As the 2026 healthcare landscape continues to evolve, the pressure on biopharma to prove lasting value will only intensify. Strategic alliances that can seamlessly stitch together the fragmented worlds of clinical research, real-world data generation, and commercial strategy are no longer just an operational convenience. They are rapidly becoming the baseline requirement for ensuring that innovative, life-saving therapies can successfully navigate the complex journey from the laboratory bench to the patients who need them most.